Clinical indications for newer antifungal agents

Journal of Hospital Medicine

Volumn 4, Issue 2, 2009, Pages 102-111

  Naeger Murphy, Nina ^a   Pile, James C ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Antifungal drugs; Aspergillus; Candidemia; Febrile neutropenia; Fungal infection

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CASPOFUNGIN; CIMETIDINE; CLOTRIMAZOLE; DEXAMETHASONE; ECHINOCANDIN; EFAVIRENZ; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; NEVIRAPINE; NIFEDIPINE; PHENYTOIN; POSACONAZOLE; PYRROLE DERIVATIVE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; RITONAVIR; STEROID; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ABDOMINAL ABSCESS; ASPERGILLOSIS; CANDIDA ABSCESS; CANDIDEMIA; CANDIDIASIS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; DIARRHEA; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDEMIC DISEASE; ESOPHAGUS CANDIDIASIS; FACE EDEMA; FATIGUE; FEBRILE NEUTROPENIA; GRAFT VERSUS HOST REACTION; HALLUCINATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPLASMOSIS; HUMAN; IMMUNOCOMPROMISED PATIENT; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LEUKOPENIA; LIVER TOXICITY; LOADING DRUG DOSE; MONOTHERAPY; MORTALITY; MUCOCUTANEOUS CANDIDIASIS; MUCORMYCOSIS; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OROPHARYNX CANDIDIASIS; PERITONITIS; PHLEBITIS; PLEURISY; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SURVIVAL RATE; THRUSH; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VASODILATATION; VISUAL DISORDER; VOMITING; XEROSTOMIA; CLASSIFICATION; DRUG THERAPY;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; AZOLES; CANDIDIASIS; DRUG THERAPY; ECHINOCANDINS; ENDEMIC DISEASES; HUMANS; MYCOSES; NEUTROPENIA; TRIAZOLES; ZYGOMYCOSIS;

EID: 65549152393     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.412     Document Type: Review

References (61)

1. Spellberg BJ, Filler SG, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis. 2006;42:244-251.
2. Bennett JE. Echinocandins for candidemia in adults without neutropenia. N Engl J Med. 2006;355:1154-1159.
3. Ostrosky-Zeichner L, Oude Lashof AML, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis. 2003;22:651-655.
4. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38:161-189.
5. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofugin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020-2029.
6. Kuse E-R, Chetchotisakd P, Arns da Cunha C, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomized double-blind trial. Lancet. 2007;369:1519-1527.
7. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356:2472-2482.
8. Cornely OA, Lasso M, Betts R, et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother. 2007;60:363-369.
9. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomized non-inferiority trial. Lancet. 2005;366:1435-1442.
10. Antoniadou A, Giamarellou H. Fever of unknown origin in febrile leucopenia. Infect Dis Clin North Am. 2007;21: 1055-1090.
11. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
12. Pizzo PA, Robichaud KJ, Gill FA, et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982;72:101-111.
13. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med. 1989;86:668-672.
14. Walsh TJ, Finber RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 1999;340: 7644-7671.
15. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997;98:711-718.
16. Boogaerts MA, Maertens J, Van Der Geest R, et al. Pharmacokinetics and safety of a 7 day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrob Agents Chemother. 2001;45: 981-985.
17. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004; 351:1392-1402.
18. Marco F, Pfaller MA, Messer S, et al. In vitro activities of voriconazole and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother. 1998;42:161-163.
19. Marco F, Pfaller MA, Messer S, et al. Antifungal activity of a new triazole, voriconazole (UK-109,496) compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med Mycol. 1998;36: 433-436.
20. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225-234.
21. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46: 327-360.
22. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
23. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39:1563-1571.
24. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006;53:337-349.
25. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348-359.
26. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft versus host disease. N Engl J Med. 2007;356:335-347.
27. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44:2-12.
28. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44:1289-1297.
29. Ally R, Schürmann D, Dreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis. 2001;33: 1447-1454.
30. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36:1122-1131.
31. Villanueva A, Arathoon EG, Gotuzzo E, et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis. 2001; 33:1529-1535.
32. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med. 2002; 113:294-299.
33. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis. 2004;39:842-849.
34. Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis. 2004;39:770-775.
35. Vasquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis. 2006;42:1179-1186.
36. Skiest DJ, Vasquez JA, Anstead GM, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis. 2007;44:607-614.
37. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634-653.
38. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KVI. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30:851-856.
39. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191:1350-1360.
40. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am. 2006;20:581-607.
41. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother. 2002;46:1581-1582.
42. Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. In vivo activity of posaconazole against mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother. 2002;46:2310-2312.
43. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother. 2007;51:2587-2590.
44. Greenburg RN, Mullane K, van Burik J-A.H, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50:126-133.
45. van Burik J-AH, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006;42:e61-e65.
46. Malani AN, Kauffman CA. Changing epidemiology of rare mould infections. Drugs. 2007;67:1803-1812.
47. Perfect JR. Posaconazole. Drugs. 2005;65:1568-1569.
48. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis. 2005;41:1217-1223.
49. Saubolle MA, McKellar PP, Sussland D. Epidemiologic, clinical, and diagnostic aspects of coccidioidomycosis. J Clin Microbiol. 2007;4:26-30.
50. Gonzalez GM, Gonzalez G, Najvar LK, Graybill JR. Therapeutic efficacy of caspofungin alone and in combination with amphotericin B deoxycholate for coccidioidomycosis in a mouse model. J Antimicrob Chemother. 2007;60: 1341-1346.
51. Ramani R, Chaturvedi V. Antifungal susceptibility profiles of Coccidioides immitis and Coccidioides posadasii from endemic and non-endemic areas. Mycopathologia. 2007; 163:31-19.
52. Li R-K, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother. 2000;44:1734-1736.
53. Anstead GM, Corcoran G, Lewis J, Berg D, Graybill JR. Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis. 2005;40:1770-1776.
54. Cantanzaro A, Could GA, Stevens DA, et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis. 2007;45:562-568.
55. Stevens DA, Rendon A, Gaona-Flores V, et al. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest. 2007;132:952-958.
56. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45:807-825.
57. Gonzalez GM, Fothergill AW, Sutton DA, Rinaldi G, Loebenberg D. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med Mycol. 2005;43:281-284.
58. Connolly P, Wheat J, Schnizlein-Bick C, et al. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob Agents Chemother. 1999;439:322-328.
59. Wheat LJ, Connolly P, Smedema M, et al. Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antimicrob Chemother. 2006;57:1235-1239.
60. Freifeld AG, Iwen PC, Leisak BL, Gilroy RK, Stevens RB, Kalil AC. Histoplasmosis in solid organ transplant recipients at a large midwestern university transplant center. Transpl Infect Dis. 2005;7:109-115.
61. Restrepo A, Tobin A, Clark B, et al. Salvage treatment of histoplasmosis with posaconazole. J Infect. 2007;54:319-327.